key: cord-0973095-a146rdft
authors: Kotru, Sharda; Klimuntowski, Martin; Ridha, Hashim; Uddin, Zakir; Askhar, Ali A.; Singh, Gurmit; Howlader, Matiar M.R.
title: Electrochemical Sensing: A Prognostic Tool in the Fight Against COVID-19
date: 2021-01-23
journal: Trends Analyt Chem
DOI: 10.1016/j.trac.2021.116198
sha: c73de93757bb10fb424ef93f675276f6a9d3347b
doc_id: 973095
cord_uid: a146rdft

The COVID-19 pandemic has devastated the world, despite all efforts in infection control and treatment/vaccine development. Hospitals are currently overcrowded, with health statuses of patients often being hard to gauge. Therefore, methods for determining infection severity need to be developed so that high-risk patients can be prioritized, resources can be efficiently distributed, and fatalities can be prevented. Electrochemical prognostic biosensing of various biomarkers may hold promise in solving these problems as they are low-cost and provide timely results. Therefore, we have reviewed the literature and extracted the most promising biomarkers along with their most favorable electrochemical sensors. The biomarkers discussed in this paper are CRP, ILs, TNF-α, IFNs, glutamate, breath pH, lymphocytes, platelets, neutrophils and D-dimer. Metabolic syndrome is also discussed as a comorbidity for COVID-19 patients, as it increases infection severity and raises chances of becoming infected. Cannabinoids, especially CBD, are discussed as a potential adjunct therapy for COVID-19 as their medicinal properties may be desirable in minimizing the neurodegenerative or severe inflammatory damage caused by severe COVID-19 infection. Currently, hospitals are struggling to provide adequate care; thus, point-of-care electrochemical sensor development needs to be prioritized to provide an approximate prognosis for hospital patients. During and following the immediate aftermath of the pandemic, electrochemical sensors can also be integrated into wearable and portable devices to help patients monitor their recovery while returning to their daily lives. Beyond the COVID-19 pandemic, these sensors will also prove useful for monitoring inflammation-based diseases such as cancer and cardiovascular disease.

Viruses are nonliving entities that can replicate only in the presence of a host organism.

This ability stems from their structure, which comprises a protein capsid containing DNA or RNA fragments. In December 2019, a contagious viral infection broke out in Wuhan, Hubei province

China [1] . The pathogen responsible has been identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a part of the Coronaviridae family of viruses. Rapid global spread of the RNA-based SARS-CoV-2 has prompted extreme measures from the international community, including physical distancing, lockdowns, and travel restrictions causing severe social and economic disruptions around the globe. The World Health Organization (WHO) declared a global health pandemic on March 11 th , 2020 [2] . The urgency of the COVID-19 pandemic necessitates the identification of informative biomarkers which can be used to forecast disease progression and alert clinicians to changes in patients' health.

Mitigating the severe impact of COVID-19 on patients' health warrants an understanding of the disease's pathophysiology and clinical presentation. SARS-CoV-2 receptor binding domain (RBD) is well suited for binding Angiotensin-Converting Enzyme 2 (ACE2) receptors which are highly expressed in lung tissues, nasal mucosa, kidneys, testes, gastrointestinal tract; oral, lung and intestinal tissues. The entry of SARS-CoV-2 into host cells increases inflammation through various mechanisms; serious cases are characterized by an uncontrollable release of proinflammatory cytokines. The "cytokine storm", formally known as cytokine release syndrome (CRS), can cause serious damage to affected tissues, especially the lungs.

biomarkers (C-reactive protein, interleukins, D-dimer, TNF-α, Glutamate, pH, Hematological biomarkers).

Although some biomarkers are not specific indicators of a COVID-19 diagnosis, they may be used along with RT-PCR [14] to indicate the severity of the infection. The current gold standard for protein biomarker measurement is ELISA, which provides excellent sensitivity (<1pg/mL) [17] . Western Blot is also commonly used to provide great specificity and selectivity [17] [18] .

Alternatively, electrochemical sensing techniques involve detecting electroactive analytes in biofluids such as saliva, sweat, and blood [19] . They are easy to use and can reduce testing duration. Electrochemical sensors often involve the use of a simple technique called Cyclic Voltammetry (CV). The potential of the working electrode changes relative to a reference electrode until enough potential is supplied to drive a redox reaction of the analyte at the working electrode [20] . Faradaic current is generated and measured as electrons flow between the working and counter electrodes. A brief schematic illustrating this process is provided in Figure 1 . Ideally, an electrochemical biosensor is a self-contained, integrated device which can analyze biofluids at high sensitivity and selectivity without the need for sample preparation.

These attributes make electrochemical techniques ideal for continuous health monitoring in a pandemic where proper management of personnel and healthcare resources is critical [21] .

There is an urgent need for a real-time, non-invasive sensor that can be used in point-of-care (POC) settings or wearable devices that monitor biomarker levels outside of the hospital. While biomarker sensing protocols are well established in lab-based techniques, miniaturized and portable sensors have been the beneficiaries of more recent exploration. This new attention is due to advancements in miniaturization, optimization and performance allowed by nanomaterials [22] . Decentralized testing methods using nanomaterials such as electrochemical sensors are cheaper, easier to mass produce and more accessible than centralized lab-based techniques (LBTs) like ELISA, Western-blot and PCR. Centralized LBTs may be accessible to populations in big cities with well-established infrastructure. Populations in low-middle income countries (LMICs) may lack this infrastructure and any reliable alternatives -they would benefit from decentralized techniques like individualized electrochemical sensing [23] . Furthermore, electrochemical sensors allow for the creation of personalized multiplex or non-multiplex sensors that can be used by individuals to monitor their current biomarker levels at home. If abnormal levels (i.e. during a cytokine storm) are detected, individuals can be alerted to seek medical help. Considering the demand on hospitals during the COVID19 pandemic, developing such sensors for personal use would help identify patients in need of The purpose of this manuscript is to explore electrochemical detection of biomolecules affected by COVID-19 infection to monitor disease severity, especially when present with other diseases. While there are some excellent review papers reporting biomarkers' value for COVID-19 prognosis [15] [16] , so far none of them have explored the advantages of electrochemical sensors for the detection of these biomolecules. Table 1 . A summary of some biomarkers discussed in this paper. These biomarkers are prone to being influenced by a variety of variables. There is also a shortage of studies exploring Serum COVID-19 Concentrations. provides a summary of the biomarkers discussed in this paper. In this review paper, we discuss the progress, challenges and opportunities involved in electrochemical sensing of these molecules for researchers interested in developing prognostic tools to help address these urgent healthcare needs. Table 1 . A summary of some biomarkers discussed in this paper. These biomarkers are prone to being influenced by a variety of variables. There is also a shortage of studies exploring Serum COVID- 19 Concentrations.

Serum Concentration in COVID-19

A protein which mediates inflammation in the body [35] .

IL-6 is the main inducer for CRP production, with IL-1 enhancing it [36] .

Serum: Approx. 0.8 µg/mL [35] Severe: Approx. >10 µg/mL[ interpreted from Table 2 ] [37] IL-1β A proinflammatory cytokine that helps with the production of synoviocytes [38] and proteases for inflammation [39] .

Serum: Approx. 1.642*10^-5 μg/mL [40] Mild: 1.729-3.422*10^-5 µg/mL Severe: 2.589-4.718 *10^-5 µg/mL [40] IL-4 Immunoregulatory cytokines that help Serum: Mild:

J o u r n a l P r e -p r o o f regulate antibody production, hematopoiesis, aids in the formation of the effector T-cell response [41] .

Approx. 3 .486*10^-5 µg/mL [40] 3.25-5.550*10^-5 µg/mL Severe: 3646-10379(data favours >60) [40] IL-6 Most released cytokine by activated macrophages [42] . Induces an acute phase response Serum: 1.0*10-6 to 1.0*10-5 µg/mL [43] [44]

Severe: >= 5.5*10^-5 µg/mL High Likelihood of Mortality: >= 8.0*10^-5 µg/mL [45] lL-8 A chemokine (CXL8) that is linked to the progression of ARDS [46] .

Has a key role in neutrophil recruitment [47] Serum:

1.29 ± 1.393*10-5 µ g/mL [48] Severe: >= 5.0*10^-5 µg/mL [49] IL-10 Inhibits the activity of Th1, natural killer cells, and macrophages. All these are used for pathogen expulsion [50] . In this section, we describe the physiological processes that lead to COVID-19 infection.

One of the avenues SARS-CoV-2 uses to enter the body is Angiotensin-Converting Enzyme 2 (ACE2), which can be found in the heart, lungs, kidneys, and endothelium [56] . ACE2 allows for the degradation of angiotensin II, affecting the constriction and dilation of vessels in the circulatory system in order to regulate blood pressure [57] . The virus' spike (S) protein, consisting of S1 and S2 subunits, facilitates viral entry [58] . The S1 subunit is responsible for viral attachment to the target cell's membrane via ACE2, while the S2 domain mediates the viral envelope's fusion with the host cell [58] . The viral genome then enters the host cell's cytosol, and the infection ultimately spreads to other cells.

SARS-CoV-2 infection first triggers the body's innate immunity, which serves to quickly and non-specifically prevent the spread of the virus within the body [59] . [60] . These host responses include the release of pro-inflammatory cytokines such as Interleukin-6 (IL-6) and

Tumor Necrosis Factor Alpha (TNF⍺) [61] which recruit leukocytes to help the body fight infection [62] . However, in severe cases, systemic inflammation can give rise to respiratory, cardiovascular, or neurological complications [63] . For instance, the IL-1β and IL-6 released during a COVID-19 infection can lead to lung inflammation, fever, and fibrosis [64] .

The release of pro-inflammatory cytokines activates the adaptive immune system, which includes T-and B-lymphocytes. T-lymphocytes like Cluster of Differentiation 4+ and 8+

(CD4+ and CD8+) are memory cells that 'remember' antigens, allowing them to destroy infected J o u r n a l P r e -p r o o f host cells and subsequently recruit other immune cells to do the same [65] . B-lymphocytes facilitate the production of antibodies which attach to the antigens and mark them for destruction [65] . COVID-19 patients may present with lymphocytopenia (lymphocyte deficiency), which slows their immune response to the infection [66] . Lymphocytopenia has been reported in only 25% of mild COVID-19 cases [42] but in 80% of critical cases [57] . When T-cells are overstimulated with antigens they gradually enter a state of exhaustion in which they exhibit weaker effector function [66] . Since the pathogen is still present, pro-inflammatory cytokines are released in a positive-feedback loop. The resulting "cytokine storm" can lead to ARDS, sepsis, or multiple organ failure [63] . Since pro-inflammatory cytokines play a key role in the severity and progression of COVID-19, it is critical to investigate their validity as biomarkers of the disease.

Inflammation is a complex biological process in which a symphony of markers and cells react to harmful stimuli. These markers include cytokines, immune cells, glutamate, pH and other proteins. Cytokines are signaling proteins that allow damaged tissues and immune cells to communicate [67] . Pro-inflammatory cytokines are a class of cytokines primarily released by macrophages and helper T-cells (TH) to upregulate inflammatory reactions [68] . IL-1, IL-6, Tumor Necrosis Factor (TNF-α), and IFN-γ belong to the proinflammatory class of cytokines [67] [69]. Anti-inflammatory cytokines have the ability to inhibit the synthesis of proinflammatory cytokines. Two major cytokines in this class are IL-4 and IL-10 [68] . The aforementioned cytokines can be found in measurable quantities in various biofluids, indicating the health status of a patient. Such possible biofluids include whole blood, serum, urine, saliva and sweat.

Non-cytokine protein biomarkers like CRP and D-dimer can also be found in some of these biofluids, they also indicate infection in the context of COVID19 [15] [51] . Non-protein biomarkers like pH and glutamate have also been effective in assessing pulmonary inflammation (using breath) [70] [71] [72] and neurological status, respectively [11] [73] .

Hematological biomarkers, which can be cells or cell fragments, can indicate inflammation through the fluctuation of their concentrations in whole blood. COVID-19 specific biomarkers such as N-protein, S-protein, and viral RNA can specifically diagnose COVID-19 unlike the previously mentioned biomarkers and these biomarkers can help indicate disease severity.

Out of the aforementioned biofluids, whole blood and its' derivatives (serum, plasma, etc.)

are considered invasive because they require medical professionals to cut the skin or insert instruments into bodily openings. Whole blood is the biofluid gold standard of bioassays. It is a simple, well-defined broad appraisal of the human immune response. Drawing blood would not provide a real-time assessment of health status and repeated blood harvesting leaves patients susceptible to infection by creating avenues for pathogen entry. This can be especially dangerous in an overcrowded hospital setting where bacteria and viruses tend to be strong and drug-resistant, as is the case during the current pandemic. This could be overcome with implanted sensors, however; they are invasive and lack commercial viability [74] . Whole blood contains many potential interfering compounds, and tends to foul electrode surfaces, negatively impacting their performance [75] . This provides an opportunity for development and validation of anti-biofouling modifications [75] . Serum is derived from the centrifugation of invasively obtained whole blood without anticoagulants. Serum analysis does not suffer from the interference and fouling issues of whole blood analysis, but it is time-consuming to harvest J o u r n a l P r e -p r o o f and requires external lab equipment. Nevertheless, non-invasive biofluid alternatives like saliva, sweat, breath, and urine are also viable. In particular, saliva contains many of the constituents found in serum due to transcellular and paracellular routes between blood and saliva [76] .

However, the concentration of various biomarkers is much lower in saliva compared to blood, providing a technological challenge for researchers [76] . Despite this, more sensitive materials are being used in biosensors, which has rendered the diagnostic/prognostic utility difference between saliva and blood less apparent [75] [76] . Saliva can contaminate breath, which is another non-invasive biofluid that contains a variety of biomarkers that can be sensed. Breath provides insight into the health status of the lungs, and it is easy to sample. Sweat is also a noninvasive matrix. Studies have found similar IL-1α, IL-1β, IL-6, IL-8, and TNF-α concentrations between plasma and sweat [43] . One challenge with sweat analysis is the need for an adequate amount of fluid to be harvested; perspiration may vary among individuals and thus presents an obstacle to researchers [77] . Urine testing is a reliable and ubiquitous option, however its collection can also cause discomfort, risk disease transmission, and requires the handling of noxious fluids. Lab testing on urine is subject to time and temperature factors affecting particle stability [78] . Testing within two hours of collection is considered optimal, however, point-ofcare testing is not subject to these limitations [79] . Despite the difficulties in collecting and measuring the aforementioned biofluids, they can quickly provide valuable information about patients' health, especially when used in the context of electrochemical sensing. This section will describe some promising electrochemical sensors and the analytes they sense.

J o u r n a l P r e -p r o o f Biofouling has been identified as an important factor for prognostic sensors.

Researchers designing sensors in the wearable or implanted sensor space will be prioritizing reusability in their design. The greatest obstacle these designers will face is biofouling at the surface of the electrode following repeated sensor use. This phenomenon blocks the transfer of electrons from the analyte to the electrode, diminishing the sensor's performance. Biofouling can occur by two mechanisms; it can affect the recognition components (including antibodies and aptamers), or the transducing components (including the electrode surface). The recognition element is affected by the non-specific adsorption of proteins present in the biofluid onto analyte receptors [80] . The transducing element is affected when an analyte in the sample participates in a redox reaction and forms electrochemically inactive products on the electrode surface [81] .

Many anti-fouling strategies have been envisioned to treat the fouling of these components actively and passively. Passive anti-fouling takes advantage of material properties to promote the release of adsorbed proteins or render surfaces thermodynamically unfavourable for fouling material attachment [82] . Polyethylene glycol (PEG) and hydrogels form polymeric networks which retain water, thus forming a hydrophilic barrier on the electrode surface to which proteins have difficulty binding due to entropic unfavourability [82] .

Active anti-fouling strategies utilize stimuli-responsive materials to reversibly change a material's properties. Mechanical stress, light, pH, temperature, acoustic waves or electrical/magnetic fields have been used in active anti-fouling sensors [83] [84] . Temperature kinetics were all considered. This presented an active anti-fouling design that could take advantage of the body's own fluctuations in temperature to "clean" the electrode surface [84] .

Ultimately, a similar demonstration of anti-fouling capabilities will be essential in real-sample analysis of complex matrices such as blood, urine, saliva and sweat. CRP is a ring-shaped plasma protein produced in the liver [85] . Generally, CRP is a nonspecific indicator of tissue damage, infection, and other forms of acute inflammation [86] .

Non-infected individuals have a median baseline concentration of 0.8 µg/L; up to 10 µg/L at the 99th percentile [35] . During inflammatory events, CRP can increase by more than 1000-fold, reaching between 100 μg/L and to 500 mg/L [86] . This large range makes changes in health status obvious as it provides an indication of inflammation along with an assessment of the intensity of the inflammation or infection [86] . During a COVID-19 infection, CRP levels can range between 1 µg/L (very mild cases) to more than 100 µg/L (severe cases) [15] . Future electrochemical sensors must operate in a wide linear range, ideally able to sense concentrations between 0.8 µg/L and 500 mg/L. There are a lack of studies indicating CRP presence in sweat, but there is evidence of CRP being present in saliva and blood [37] . Given the non-specific nature of CRP, biosensors targeting CRP will find many other applications such assessing autoimmune disease, the likelihood of developing CVD, amongst other conditions involving inflammation [86] . Evidently CRP is a viable biomarker for COVID-19 prognostics, meriting the exploration of various electrochemical sensors that measure this analyte. Some existing CRP electrochemical sensors are listed in Table 2 . Unfortunately, most approaches to sensing have failed to detect CRP outside of a narrow concentration range, while the clinical nature of the analyte necessitates a wide dynamic range (pM to µM) [87] . Additionally, most protocols are multistep and require extra processing, making them difficult to adapt to continuous or wearable devices [87] . One sensor that addressed both of these issues was based on an electrolyte-gated organic field-effect transistor (EGOFET) sensor that was fabricated through the absorption of anti-CRP monoclonal antibodies onto a poly-3-hexyl thiopene (P3HT) semi conductive organic surface [87] .

Afterwards the modified semiconductor surface was treated with hydrophilic (N-[tris(hydroxymethyl) methy] acrylamide-lipoic acid conjugate (pTHMMAA)) polymer to properly orient the anti-CRP antibodies and block non-specific binding. The linear range of this sensor was 4 pM to 2 μM (equivalent to 220 ng/L to 200 mg/L), and the limit of detection was 2 pM, which is ideal for COVID-19. Beyond COVID-19, this range enables assessment of inflammation, cardiovascular health, and cancer [88] . This label-free sensor was compatible with disposable and flexible substrates while being adaptable to miniaturization and multianalyte arrays. An electrochemical capacitance immunosensor that used an interdigitated wave-shaped microelectrode array showed high performance (shown in Figure 2 ) [89] . A self-assembled Dithiobis (succinimidyl propionate; DTSP) monolayer functionalized by NaBH4 was used to anchor anti-CRP antibodies onto the electrode surface. The sensor had a linear range of 0.01 ng/mL to 10000 ng/mL (equivalent to 10 ng/L to 10 mg/L); this inadequately covered expected CRP concentrations in severe COVID-19 cases, but future developments may increase this range. The sensor was found to produce ideal electrochemical responses at a pH value of 7.4, a 50 µg/mL anti-CRP-antibody concentration and a ten-minute incubation time. The sensor was able to detect CRP without significant effects from a high concentration of interfering agents. It had a miniaturized design, good storage stability (two weeks at 4°C) and was easily adaptable to a microcontroller-based potentiostat. Despite these advancements, there is a shortage of CRP electrochemical sensors with an optimal linear range for COVID-19 applications. Future research should focus on developing sensors with wide linear ranges and improved usability for POC applications.

J o u r n a l P r e -p r o o f [106] . Out of these, IL-6 was most examined by the literature as a target for COVID-19

prognostics, and several IL-6 receptor inhibition therapies are currently being investigated [107] [108]. In addition, interleukins can be detected in a variety of biofluids such as blood, saliva [109] , sweat [110] , and even breath [111] . IL-1α IL-1β, and IL-6 concentrations in sweat were not different from plasma, with healthy levels ranging between 1-10 pg/mL [43] [44] . Metaanalysis of COVID-19 patients found IL-6 serum concentrations ≥ 55 pg/mL indicated a high risk for developing a severe COVID-19 infection, and concentrations ≥ 80 pg/mL indicated a high risk J o u r n a l P r e -p r o o f of mortality, although only one study examined this endpoint [45] . A meta-analysis found IL-6 serum concentrations were 2.9 times greater in severe cases compared to non-severe cases [112] . COVID-19 treatments like corticosteroids and drugs targeting proinflammatory signal pathways can be guided by interleukin biosensors to gauge efficacy and adjust treatment dosages [113] . Examples of these drugs include Tocilizumab (targeting IL-6) and Anakinra (targeting IL-1) [113] . Beyond their use in COVID-19 therapies and prognostics, interleukin biosensors will find applications in assessing conditions such as cancer [114] , aneurysms [115] , and Chronic Obstructive Pulmonary Disease (COPD) [116] . Electrochemical sensing developments for the measurement of interleukin levels are abundant due to their diverse applications, but performance differs between sensors.

J o u r n a l P r e -p r o o f Reprinted and adapted with permission from ref [117] . Copyright 2018 American Chemical Society. Table 3 presents some electrochemical interleukin biosensors. These sensors are highly specific due to their use of antibodies to bind to specific interleukins [17] . Sensors for IL-6 have achieved levels of detection which can distinguish between severe and non-severe cases of

Biomarker (dLABer), combined breath sampling, microfluidics, and a silicon nanowire field effect transistor (SiNW-FET) biosensor to measure the quantities of IL-6 in exhaled breath [117] .

The breath exhaled by rats was absorbed with the collection liquid PBS via an airflow system, revealing IL-6 concentration. The dLABer had a signal-to-noise ratio 104 times higher than that of the ELISA when analyzing the same breath samples [117] . It was determined that the ELISA and sensor data were in agreement and the sensor demonstrated good repeatability and selectivity amongst ambient components. However, this method has only been tested on the exhaled breath of mice and further work is needed to adapt the breath collection component to human breath. Furthermore, the lower limit of the range of detection is 5 pg/mL which means it may be used in COVID-19 monitoring. However, this may restrict the applications of this sensor from conditions such as some forms of cancer [118] . This sensing technique can potentially be combined with ventilators to analyze patients' exhaled breath in intensive care settings to alert clinicians of alarming interleukin spikes. The use of breath to measure interleukin levels has proven to be possible and presents an opportunity for future research. Tumor Necrosis Factor (TNF) is a potent pleiotropic cytokine playing important roles in cell proliferation, differentiation and apoptosis [53] [54] . It is one of the most thoroughly studied cytokines and is considered the "master-regulator" of immune homeostasis by limiting the duration of the inflammatory process [125] [126] . TNF is responsible for initiating strong inflammatory responses, inhibiting autoimmune diseases and impeding tumor growth [126] .

Anti-TNF antibodies have been used to treat autoimmune diseases like rheumatoid arthritis (RA), inflammatory bowel disease (IBS), or ankylosing spondylitis [127] . TNF has also been found to increase during COVID-19 infection and the resulting cytokine storms, although exact Table 4 To address the challenges of the COVID-19 pandemic (for example, alerting clinicians to the onset of cytokine storms) a label-free, wearable sensor is desired. One study artificial tears [135] . Tween 80 was also used to protect the long-term stability of the sensor and block the potentially interfering molecules by passivating the unmodified graphene area.

Although electrochemical TNF sensors can decrease assay time from several hours (ELISA) [117] [136], future TNF sensors must emphasize timely/continuous detection. Interferons (IFNs) are a class of cytokines that interfere with viral and non-viral infections in the body by adapting cell functions [137] . IFN-α and IFN-β are typically produced by infected cells, while IFN-γ is produced by T-lymphocytes during cell division [138] . The Table 4 ) but do not seem to be as relevant to COVID-19 prognosis. This presents an opportunity for future research and sensor development. [146] .

The presence of coronaviruses in the CNS may also result in long-term neurological diseases [9] [147] . Coronaviruses can reach the smell center of the brain, primarily via vascular cells in the CNS [148] . Olfactory cells in the nasal cavity are most vulnerable to viral infection [148] . The first neurons infected are the neurons that detect odors in the nasal cavity and can also signal when a virus is present to summon other brain and immune cells to help fight the infection [9] [149] . The virus not only affects the respiratory system, but also has deleterious effects on the CNS [149] . During the SARS (severe acute respiratory syndrome) epidemic in 2003, the SARS coronavirus was also found to attack the CNS causing brain and spine demyelinating lesions and neurodegenerative diseases (e.g. multiple sclerosis, Alzheimer's disease, and Parkinson's disease) [10] [11] . Brain stroke and seizures are already reported to be associated with coronavirus [73] . Neurological symptoms manifest in a notable proportion of patients with coronavirus disease [147] . As a possible explanation of neurotoxicity due to virus invasion, some coronaviruses have demonstrated the ability to spread via a synapse-connected route to the medullary cardiorespiratory center from the mechanoreceptors and chemoreceptors in respiratory system [149] .

J o u r n a l P r e -p r o o f Reprinted and adapted with permission from ref [150] . Copyright 2013 Elsevier. B) Schematic of an enzymatic L-glutamate biosensor. The exposed copper wire makes contact with the potentiostat while the epoxy tip comes in contact with L-glutamate. Reprinted and adapted with permission from ref [151] . Copyright 2019 Elsevier.

Since glutamate is the most abundant excitatory neurotransmitter in the CNS and neurotoxicity in COVID-19 evident, a glutamate-related biomarker can play an important role in detecting the severity of neurotoxicity. One major limitation, however, is that glutamate concentrations in some biofluids are lower than the detection limits of existing electrochemical sensors [55] . To address this, the functionalization of nanomaterials used for sensing (for example, NiO and Co 3 O 4 ) can be improved with carbon nanotubes or β-cyclodextrin may improve sensing performance. Figure 5 shows an example of one glutamate sensor made with Ni nanoparticle coated Pt electrode surfaces. A recent review identified the connection of glutamate to pathologies as a potential biomarker and emphasized development of electrochemical sensors to instantaneously detect glutamate in biofluids [55] . This review analyzed the performance of various materials for the working electrode of a non-enzymatic glutamate electrochemical sensor.

J o u r n a l P r e -p r o o f 

pH as a biomarker is difficult to assess at times due to the great number of variables that affect it in various biofluids [55] . Despite this difficulty, Exhaled breath condensate (EBC), J o u r n a l P r e -p r o o f the condensed liquid form of exhaled breath, has been reliably observed to experience pH changes, resulting from inflammation caused by pulmonary diseases such as asthma, COPD, and cystic fibrosis [70] . Such diseases cause oxygen limitations for lung cells, and this hypoxic state drives the cell into anaerobic respiration in which lactic acid is produced as a byproduct. In diseased states, EBC pH levels drop to a range of 4 -6 while healthy patients' pH levels are around 7.4 or higher [156] . EBC pH can indicate inflammation even before clinical presentation of lung injury is observed [157] [158] [159] . A study examined patients requiring ventilation (with and without signs of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)) and found that EBC pH in ventilated patients was lower and lactate levels were higher relative to a healthy group [157] . Furthermore, proinflammatory cytokine concentrations in breath correlated with both lower EBC pH and increased disease severity. To the best of our knowledge, no relationship between COVID-19 infection/severity and breath pH has been investigated. However, since viral infections commonly cause lung inflammation, breath pH may provide valuable insight into a patient's condition in the context of COVID19. Thus, new research concerning this relationship is encouraged.

Unfortunately, collection of breath samples poses a risk for contamination. Most air contained in the respiratory tract does not contact the bloodstream at the alveoli; this is known as "dead-space air" [160] . During sample collection dead-space air dilutes the sample containing clinically significant molecules. This issue can be overcome by exclusively sampling air exhaled at the end of breath [160] . Also, Volatile Organic Compounds (VOCs) in atmospheric air may enter the respiratory tract during inhalation and contaminate the sample. In this case, correction for background concentrations of VOCs by parallel sampling of breath and external J o u r n a l P r e -p r o o f air is necessary [160] . Additionally, it is possible for breath samples to be contaminated by saliva, so collection techniques need to account for the separation of these matrices. They may also be harvested and analyzed in parallel to maximize usability of the data collected. Various collection methods have been devised to avoid contaminants in EBC samples; a few of them are discussed below.

To capture exhaled breath for analysis, a simple condensation method is required [161] .

In addition to a cooling system, gas standardization (de-aeration) may be used to address the issue of CO2 contamination, which can decrease the measured EBC pH values [162] . Two such collection devices are shown in . A saliva filter is often used to ensure the breath condensate is not contaminated by saliva [161] . One proposed EBC collection mechanism was a system that attached to the exhaust port of a standard Servo-i hospital bedside ventilator [163] . This device included 2-chamber gas-standardization with a pH sensor that measured pH every 6 seconds.

Extracting exhaled breath condensate during ventilation was also deemed to be nondetrimental to the patient and the apparatus [164] . This device would benefit from newer fabrication technologies, such as 3D printing, or new materials which could optimize cooling and hydrophobicity.

J o u r n a l P r e -p r o o f There are a variety of ventilator-independent commercial devices (Ecoscreen, RTube) used to collect EBC, however, their high costs restrict widespread use [165] . To address cost concerns, a device using only a stainless-steel open cylinder, a tube acting as a mouthpiece, and a syringe was developed [165] . The metal tube was placed in dry ice for five minutes and then patients exhaled into the tube. A sensor then measured pH levels despite not de-aerating the sample. CO2 present in exhaled breath lowers pH and necessitates the same collection-toanalysis time for consistent measurements [165] . This low-cost collection device is attractive to areas where healthcare may not be widely accessible due to costs. The two devices described here can be adapted for COVID-19 prognosis or assessing pulmonary injuries like ALI, COPD, and asthma.

Lymphocytopenia, neutrophilia and thrombocytopenia are present in severe and less pronounced in non-severe COVID-19 patients [166] . Therefore, lymphocyte, neutrophil, and platelet counts are all potential biomarkers that may aid in the prognosis of a COVID-19

infection. SARS-CoV-2 has a direct effect upon lymphocyte count, infecting T-cells directly, and the final result is a decrease in CD3+, CD4+, and CD8+ T lymphocytes accompanied by an increase in regulatory T-cells [167] . More lymphocyte apoptosis also results from the subsequent cytokine storm [167] . Lymphocyte count has already been combined with either platelet or neutrophil count, using ratios like neutrophil-lymphocyte ratio (NLR) and plateletlymphocyte ratio (PLR); both of which are more predictive of disease state compared to sampling each biomarker alone [167] . Despite the potential of hematological biomarkers, WBC counts are subject to change due to simultaneous viral or bacterial infections [168] . Steroids Table 6 . One publication documents a portable, label-free, paper-based smartphone compatible sensor with gold microelectrodes [171] as seen in Figure 7 . A polyvinylidene fluoride (PVDF) membrane (paper) was used to physically trap WBCs, while interdigitated microelectrodes were used with ferrocyanide probes to quantify the trapped WBCs [171] . A portable potentiostat was also constructed with an Arduino UNO and two operational amplifiers; it was used to conduct differential pulse voltammetry (DPV) and send the collected data to a nearby smartphone via Bluetooth [171] . Furthermore, the dynamic range of this sensor was 100 -10000 cells/uL [171] . This covered most cases of leukocytopenia and leukocytosis, including severe leukocytopenia caused by COVID-19 (approx. 2000 cells/uL) [171] [172]. This system's smartphone compatibility made data collection, storage, and analysis very quick, rendering it suitable for application in POC settings. The portable and cost-efficient nature of the Arduino potentiostat is also noteworthy; it paves the way for such electrochemical sensors to be used by patients at home in a similar fashion to blood-glucose testing in diabetics. Since the long-term effects of the COVID-19 infection are unknown, this feature could be especially useful for patients who have been discharged from the hospital and want to keep track of their recovery. This study takes steps to better sensor accessibility and ease-of-use while highlighting the opportunity to improve system design for sensors of other biomarkers mentioned in this review. D-dimer is a protein fragment produced as a by-product of fibrinolysis, the process of thrombus-breakdown in the body [51] . It can be used to detect clotting abnormalities that arise when blood coagulation and fibrinolysis fall out of balance [51] . D-dimer is commonly measured in plasma, but techniques have been developed to allow measurement through saliva as well [177] . Although D-Dimer can be elevated due to non-pathological factors such as race, age, or smoking, it is also elevated during pathologies such as stroke, atrial fibrillation, malignancy, or even COVID-19 [51] . One study (n=248) found that 74.6% of COVID-19 patients had elevated D-J o u r n a l P r e -p r o o f dimer levels (>= 0.5mg/L), and the median D-dimer levels were higher in non-survivors (6.21 mg/L) than in survivors (1.02 mg/L) [52] .

D-dimer is a valuable biomarker to measure in COVID-19 patients as soon as the infection is diagnosed. One study has found that D-dimer levels greater than 2.0 µg/mL on hospital admission can predict mortality with a sensitivity of 92.3% and specificity of 83.3%, regardless of the patient's symptom severity [178] . Using electrochemical sensing techniques to monitor D-dimer early and frequently can allow health-care professionals to administer antithrombotic therapies if needed and prevent fatalities [179] . Furthermore, COVID-19

patients with metabolic syndrome are more likely to suffer cardiac events as the infection progresses [180] , and D-dimer sensing could be valuable in predicting and intervening in those events. Monitoring D-dimer values after COVID-19 recovery may also be an important tool to preserve long term health for patients. It is possible that COVID-19, like its close relative SARS-CoV, leaves long lasting damage [181] . This can lead to cardiovascular events many years after recovery [182] . However, obtaining blood samples for D-dimer testing is an invasive procedure that may cause patients discomfort and increase chances of infection. Urine testing is reliable and ubiquitous but is subject to similar difficulties as blood, although it is less invasive. Despite these barriers, D-dimer's early elevation in response to infection, along with its strong predictive value make D-dimer electrochemical sensing an opportunity worth exploring. Over the past decade, several electrochemical immunosensors have been developed to measure D-dimer levels in biofluids; some of these sensors are listed in Table 7 . One such sensor has an especially low-cost desktop fabrication method that could be valuable in areas where cleanrooms and expensive lab equipment are scarce [184] . The device was fabricated using a standard 4.7-inch Sony polycarbonate compact disk (CD). After removing the protective layer from the CD with a knife, the disk was mounted onto an old CPU fan and spin-coated with photoresist (PR). The PR patterns were then exposed and developed, and electrodes were providing results within minutes while an ELISA can take hours. Since this was just a preliminary study done with the intention of validating a low-cost fabrication method, the sensor's limit of detection and dynamic range are not optimized to COVID-19. Infected individuals typically have blood D-dimer levels greater than 500 ng/mL, but this sensor's dynamic range is 1 pg -10 ng/mL. This sensor requires further testing and optimization before it can be applied to a COVID-19 patient. However, it provides a promising fabrication method that can make D-dimer prognosis technology available even in areas with funding limitations. 

Section Summary: In addition to the biomarkers mentioned previously, there have been advances in electrochemical sensing for biomarkers such as viral proteins and viral RNA specific to COVID-19. This section discusses these markers in detail, presents a few promising sensors, and identifies an opportunity for further investigation. Table 8 (entries [1] [2] [3] [4] , and two such sensors are discussed in further detail below.

A non-enzymatic electrochemical sensor has been developed to rapidly detect the SARS-CoV-2-S-RBD (S Receptor Binding Domain, Spike protein) for diagnostic purposes [189] . This sensor is composed of cobalt functionalized TiO2 nanotubes which are relatively inexpensive to synthesize and have high sensitivity. A potentiostat was used to collect the data, and the limit of detection and sensitivity were found to be 0.7 nM and 14-1400 nM respectively. This test only took ~30 seconds, making it a potential replacement for diagnostic tests that currently take several days. Furthermore, the metallic layer of this sensor can be redesigned for compatibility with other proteins, making it useful for diagnosing infections other than just COVID-19. Overall, this is a cost effective and sensitive sensor that can be adapted to other proteins, making it ideal for diagnostic applications during the current pandemic and potentially future ones as well. Another electrochemical sensor developed for sensing SARS-CoV-2 spike J o u r n a l P r e -p r o o f protein has even undergone trials in a clinical setting [190] . This graphene FET-based sensor is fabricated by first etching a graphene base, then forming an Au/Cr layer and immobilizing SARS-CoV-2 spike antibodies on top of it. The sensor's testing was done with secretions from nasopharyngeal swabs of both infected and non-infected individuals. In this medium, the limit of detection was discovered to be 242 copies/mL. Although this is greater than the limit of detection for current molecular diagnostic tests (~50-100 copies), it is still suitable for practical use, and is one of the only current COVID-19-specific sensors that has undergone clinical trials.

These two sensors are currently the most promising in the detection of viral proteins specific to COVID-19.

Despite the promising capabilities of the above-mentioned sensor, there remains a need for non-COVID-specific sensors that can be useful far beyond the end of the pandemic. At the present time, viral protein or RNA sensors will be a great help in diagnosing infected individuals.

Post-infection, long term cardiological, neuropathological or inflammatory problems will be difficult to track using a COVID-specific sensor. Developing technologies for non-specific sensors will serve multiple purposes -inflammatory responses in patients can be monitored both throughout the infection and during recovery by continually tracking one or more inflammatory markers starting from the day of diagnosis. One such sensor is discussed in detail below.

A graphene-based multiplexed electrochemical sensor has been developed to diagnose COVID-19 and determine which stage of infection the patient is in [191] . It measures the concentration of four analytes: SARS-CoV-2 nucleocapsid protein (NP), CRP, and SARS-CoV-2 spike protein immunoglobulins S1-IgM and S1-IgG. The varying concentrations of these J o u r n a l P r e -p r o o f biomarkers in saliva or serum are used to distinguish between healthy, recovered, and infectious patients with varying degrees of symptom severity (presymptomatic, asymptomatic, symptomatic). Testing patient samples with this sensor can take as little as 1 minute, and the materials used in its fabrication are also low cost. The design involves four laser-engraved electrodes functionalized with antibodies or coating proteins specific to each analyte. NP and CRP are detected via a sandwich-type assay, while S1-IgM and S1-IgG are detected via a doublesandwich type assay. Overall, this sensor utilizes inflammatory biomarkers and COVID-19 specific markers to diagnose the infection and determine its severity within minutes, making it an ideal device for use in POC settings. However, the use of this sensor requires the dilution of saliva and serum samples with PBS, which hinders the application of the system in at-home settings. This shortcoming is present in many of the other sensors discussed in this review as well. Moving forward, such multiplexed sensors can be designed to detect even more biomarkers such as ILs and IFNs, which may allow doctors to identify symptomatic patients in need of more direct attention or urgent care. Furthermore, the avenue of multiplexed sensors that measure COVID-19 specific and non-specific markers should be further explored to improve the simultaneous diagnosis and prognosis of COVID-19. Complementary thiolated probes n/a n/a n/a [193] Viral nucleocapsid phosphoprotein (Ngene)

Electrode made of AuNPs on graphene film

Highly specific antisense oligonucleotides (ssDNA) Pharmaceutical Preparation 6.9 5.85*10^7-1*10^9 [194] +Spike protein Graphene FET-based sensor with Au/Cr electrodes SARS-CoV-2 spike antibody Nasopharyngeal secretions from COVID-19 infected individuals 242 n/a [190] Multiplex sensor for SARS-CoV-2 nucleocapsid protein (NP), S1-IgM, S1 IgG, and CRP

Laser-engraved graphene electrodes, sandwich/doublesandwich type assay (depending on the analyte) Capture antigens and antibodies for NP, S1-IgM, S1-IgG and CRP immobilized onto the graphene electrode surface Serum and saliva samples from RT PCR-confirmed COVID-19 positive patients and healthy patients n/a n/a [191] 1 The units used are copies/mL unless otherwise noted. J o u r n a l P r e -p r o o f Metabolic syndrome and its accompanying conditions are comorbidities that are often associated with COVID-19 [13] . Metabolic syndrome refers to a collection of risk factors such as obesity, insulin resistance/hyperglycemia, endothelial dysfunction, or hyperlipidemia that can increase a patient's chance of having type 2 diabetes or atherosclerotic cardiovascular disease (CVD), leading to a heart attack or stroke [195] . Since ACE2 is an enzyme involved in managing blood pressure, ACE2 expression is often elevated as a result of metabolic syndrome [196] .

ACE2 also serves as SARS-CoV-2's primary target, so patients with metabolic syndrome are more frequently infected by COVID-19, and often suffer more severe infections than those without metabolic syndrome [13] . For instance, a study conducted in China showed that the case fatality rate for COVID-19 patients was 2.3%, but in patients with hypertension, diabetes, and CVD, it was 6%, 7.3%, and 10.5% respectively [197] . Since metabolic syndrome is a relatively well researched condition, knowledge about its symptoms, biomarkers, and management can be used to improve COVID-19 treatment outcomes for patients with metabolic syndrome.

Metabolic syndrome and its associated illnesses are commonly accompanied by chronic systemic inflammation, which overloads patients' immune and cardiovascular systems [13] [ 198] . In COVID-19 patients this is compounded by the inflammation from the infection, and the excess of inflammatory cytokines can lead to a fatal cytokine storm [199] . Several biomarkers can be used to monitor the progression of inflammation in metabolic syndrome, including proinflammatory cytokines such as IL-6, TNF⍺, and CRP [200] . IL-6 is a proinflammatory cytokine released upon any disruption of homeostasis in the body, but in the cardiovascular system, it is released primarily in response to vascular tissue remodeling. Initially, elevated J o u r n a l P r e -p r o o f levels of IL-6 have a protective effect by directing the immune system to injured tissue and facilitating healing [201] . However, chronically high levels of IL-6 induce systemic inflammation and are causally linked to CVD [201] . Similarly, TNF⍺ is a cytokine that contributes to heart contractility and peripheral resistance [202] , but chronically elevated levels can promote atherosclerosis by inducing vascular dysfunction [203] . CRP is a biomarker that is very predictive of acute myocardial infarctions, and levels higher than 10 mg/L (in blood) give patients at least a 4% risk of experiencing a fatal cardiovascular event over the next ten years [204] . Recent investigations have proven that these biomarkers can be monitored in saliva as well [205] [200] . During a COVID-19 infection, many of the same biomarkers are further elevated (CRP, IL-6, TNF⍺, etc.) [16] , making them perfect targets for a biosensor that can be used to monitor concentrations of inflammatory cytokines as the infection progresses. Several examples of these sensors were discussed above in Section 3. This way, severe outcomes of the infection can be mitigated, especially in patients with metabolic syndrome which predisposes them to cardiac events and other fatalities.

Since the virus largely targets cells of the cardiorespiratory system it is possible that recovered patients are more likely to experience strokes or cardiac events long after they have recovered from COVID-19. This link has been found in a close relative of SARS-CoV-2, SARS-CoV [181] . In one study, patients were surveyed 12 years after recovery from a 2003 SARS-CoV outbreak [181] . It was determined that 68% had hyperlipidaemia, 60% had glucose metabolism disorders, and 44% had cardiovascular disorders. They were also more likely to contract lung infections and develop tumors. Although the mechanisms of these long-term health detriments are unknown, the correlations have been established. It is possible that this correlation applies J o u r n a l P r e -p r o o f to SARS-CoV-2 as well, and it can be especially damaging for patients with the metabolic syndrome comorbidity. Research is currently being conducted to develop therapies for COVID-19 in the short term, but as the pandemic fades, it will become important to monitor patients with comorbidities who can suffer fatal outcomes years after recovery. It is possible that tracking inflammatory biomarkers in COVID-19 patients now will give medical professionals insight into the long-term effects of the infection. Simultaneously, it will prepare them for outbreaks that may arise from similar viruses in the future. [225] and mental illnesses like anxiety and depression [226] . They do this via four pathways involving the cannabinoid receptor 2 (CB2) which is highly expressed on the surface of immune cells [227] . The four pathways are apoptosis, inhibition of cell proliferation, cytokine/chemokine production inhibition and regulatory T cell induction [227] . In general, limited evidence exists concerning the influence of cannabinoids on patients with viral infections, and no investigations are available regarding SARS-CoV-2.

The novel interest in medicinal cannabis has led to a surge in evaluations and validations of therapeutic application for Cannabis, including viral infections [228] . Although cannabis contains therapeutic potential for many diseases, it remains unclear whether THC and CBD would be advantageous or disadvantageous in the fight against COVID-19 [228] . Cannabinoids have been shown to inhibit immune cell recruitment and function in the lungs while having detrimental effects on lung function and decreasing respiratory pathogen clearance [229] .

Understanding the role of cannabinoids in providing resistance against inflammatory damage may help clinicians with producing optimal health outcomes.

Deleterious neurological effects have been observed in a notable proportion of COVID-19 patients [147] [149] . Anosmia (loss of smell) [230] , necrotizing encephalopathy (brain damage) [231] , stroke [73] and Guillain-Barré syndrome are neurological disorders associated with COVID-19 [232] . Although the exact mechanism is unknown, increasing evidence suggests some coronaviruses use synapse-connected routes to travel from the lungs and airways to the brainstem [149] . Despite a lack of information regarding the effects of CBD on COVID-19 recovery, cannabis has been used to guard against neurological developments caused by other viral infections. Studies have suggested cannabis exposure is associated with lower levels of neurocognitive impairment for individuals living with HIV, possibly due to its anti-inflammatory effects [233] . Other studies demonstrated CBD attenuated neuroinflammation induced by Theiler's Murine Encephalomyelitis Virus-Induced Demyelinating Disease (TMEV-IDD) in the brains of infected mice [234] . Treatment with CBD reduced the migration of activated immune cells through the blood-brain barrier (BBB) and decreased the induction of proinflammatory cytokines (CCL1, CCL2, IL-1β) and vascular cell adhesion molecule 1 (VCAM-1). Reducing leukocyte infiltration and microglia activation in the brain of TMEV-IDD mice improved their motor symptoms and neuroinflammation in the chronic phase of the infection [234] .

Furthermore, in vitro studies have shown CBD to inhibit hepatitis C (HCV) replication by 86.4% at a 10 μM concentration with an EC50 (half maximal dose) of 3.163 μM, although no activity against hepatitis B (HBV) was exhibited [235] . Additionally, studies evaluating cannabis for the treatment of HBV and HCV found cannabis to be a useful adjunct to the standard interferon or J o u r n a l P r e -p r o o f ribavirin prescriptions by helping users adhere to challenging medication regimens [236] . These examples highlight the potential for cannabinoids, particularly CBD, as an adjunct to traditional antiviral therapies.

Electrochemical sensing of cannabinoids is well documented [81] . A summary of electrochemical sensors used to detect cannabinoids in aqueous solutions is presented in Table   9 . The biggest application of cannabinoid sensors is to determine impairment status of individuals. As a result, research has mostly targeted the psychoactive THC and less commonly its metabolites 11-OH-THC and COOH-THC, while the development of electrochemical sensors for CBD has been completely neglected. Figure 9 shows that THC and CBD share a similar structure. The phenol which undergoes the redox reaction is common between the two [237] .

This presents an opportunity to validate THC biosensors for the analysis of CBD. The electrochemical behavior of CBD is largely unknown; a study of CBD's faradaic efficiency, redox site and transfer coefficient will be instrumental in developing CBD targeting sensors. Other opportunities are found in simultaneous sensing of multiple analytes. A multianalyte array simultaneously tracking cannabinoids and inflammatory markers may provide researchers new insights into medicinal cannabis and its effect on the immune system. electrolytes were evaporated onto a porous electrode overlayer [238] . The overlayer's content dissolved into a sample when the two elements came into contact, allowing the sensor to be used without prior sample preparation. This sensor is presented in Figure 10b . This method achieved a limit of detection of 0.025 ng/mL and reported little surface fouling [238] . In this way the direct oxidation of cannabinoids is avoided, extending the lifespan of the sensor. J o u r n a l P r e -p r o o f THC has very low solubility (1-2 µg/mL) in water [243] . In the past this has limited the use of electrochemical sensors in real bodily fluids because the sensitivity has not been adequate for detection [81] . Unmodified screen-printed carbon and glassy carbon electrodes have been documented with high sensitivity in non-aqueous solvents [244] [245] [246] or insufficient sensitivity in aqueous solutions [239] . Electrode surface modifications have been used to solve many problems in the electrochemical sensing space [247] . Multiwalled carbon nanotubes (MWCNT) drop-casted on a carbon ink electrode have been used in a wearable ring sensor to achieve a 157 ng/mL limit of detection [248] . This sensor can simultaneously sense THC and ethanol in the saliva of impaired drivers. The fabrication of this sensor is presented in Figure 10c /d. Sensors based on Absorptive stripping voltammetry [242] , porous carbon paper [237] , molecularly imprinted polymers (MIPs) (Figure 10a ) [241] have also produced highly [241] . Copyright 2019 Elsevier. B) An electrochemical sensor in which an OX0245 mediator and supporting electrolytes are dissolved onto a porous overlayer, which eliminates sample preparation prior to electrochemical analysis. Reprinted and adapted with permission from ref [238] . Copyright 2016 Springer. C) A schematic fabrication a wearable sensor array, Ag/AgCl ink is used for contacts, carbon ink is used for working electrode which is then modified by MWCNT by dropcasting. D) The prototype for of the wearable ring sensor. C) and D) reprinted and adapted with permission from ref [248] . Copyright 2020 Elsevier.

In this review, the recent advances and current opportunities for electrochemical sensing of biomarkers related to COVID-19 and its comorbidities were discussed. We have emphasized advantages, disadvantages, and future opportunities in label-free and wearable technology to provide insight into disease progression for resource management and public health outcomes. Opportunities are present for targeting cytokines (Interleukin, TNF, IFN) and other biomarkers (CRP, NLR, PLR, D-dimer, pH and glutamate). Cannabinoids are also being explored as a possible supplement or adjunct to conventional antiviral therapies, as such continuous monitoring of cannabinoids in biofluids is desirable, particularly the nonpsychoactive CBD. The development of sensors targeting these biomolecules is likely to progress rapidly as governments fund initiatives to minimize the impact of the COVID-19

pandemic. As mentioned in the respective sections, these biomolecules are involved in many diseases and continued work would improve health outcomes. Prior to publication, researchers should validate their sensors' performance in biofluids (saliva, sweat, urine, tears, breath) to test performance in the presence of contaminants.

Multianalyte and simultaneous sensing is the newest frontier in electrochemical sensing. Multianalyte sensing could provide more rapid determination of disease progression and allow for an economical use of resources. We highlighted low-cost fabrication technologies throughout this paper and want to reiterate the importance of low-cost sensors. The WHO has developed the A.S.S.U.R.E.D criteria as a benchmark for identifying appropriate tools in areas where resources are limited. The A.S.S.U.R.E.D acronym stands for Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and Deliverable to end-users. This is especially important during the COVID-19 pandemic where surges in cases may overwhelm developing or otherwise strained healthcare systems.

This COVID-19 pandemic has been the first-time humans have experienced the effects of the SARS-CoV-2 virus, so its long-term complications are largely unknown. Like its relative, SARS-CoV, it is likely that various cardiac and pulmonary complications of SARS-CoV-2 infection will become apparent over the next few years [181] . A study that assessed patients after 12 years of recovering from SARS-CoV infection suggested that 68%, 60%, and 40% had J o u r n a l P r e -p r o o f hyperlipidaemia, glucose metabolism disorders, and cardiovascular disorders, respectively; along with an increased risk of contracting lung infections and developing tumors [181] .

Furthermore, virus-induced pneumonia survivors are at risk of having long term lung disability, with blood-gas diffusion abnormalities [249] . Lung fibrosis has also been suggested to be a longterm consequence of COVID-19 pneumonia [250] . Using portable, wearable, or POC electrochemical sensors to monitor inflammatory biomarkers after patients have recovered from COVID-19 can allow clinicians to observe residual injury and prevent any adverse effects from occurring in the future. Currently, POC testing can be made more efficient with the use of electrochemical sensors, providing real-time monitoring of various prognostic biomarkers.

Wearable and portable sensors can be sent home with patients after discharge in order to monitor their recovery. In a post-COVID world, wearable and portable sensors will become very important as they will allow people returning to their daily lives to monitor any long-term complications of COVID-19. Apart from use during the COVID-19 pandemic, the sensors discussed in this paper have a myriad of use cases in other disorders involving inflammation, infection, and even cancer. Thus, these sensors should be developed further not only in the next few years with the purpose of post-COVID usage, but in the decades to come. 

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

WHO Declares COVID-19 a Pandemic

Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis

A review of coronavirus disease-2019 (COVID-19)

Anosmia in COVID-19: mechanisms and significance. Chemical senses

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Features, evaluation and treatment coronavirus (COVID-19)

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses

SARS-CoV-2 can induce brain and spine demyelinating lesions

Neurobiology of coronaviruses: Potential relevance for COVID-19

Prevalence of metabolic syndrome in the Canadian adult population

Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies

Molecular and Serological Tests for COVID-19 a Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics

The role of biomarkers in diagnosis of COVID-19 -A systematic review

Biomarkers associated with COVID-19 disease progression

Label-free electronic detection of interleukin-6 using horizontally aligned carbon nanotubes

Detection and quantification of cytokines and other biomarkers

Cyclic voltammetry

Serology testing in the COVID-19 pandemic response. The Lancet Infectious Diseases

Cytokine and Cancer Biomarkers Detection: The Dawn of Electrochemical Paper-Based Biosensor

Polymers and organic materials-based pH sensors for healthcare applications

Cytokine patterns in patients with cancer: a systematic review

Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis

The prognostic and pathophysiologic role of pro-and antiinflammatory cytokines in severe malaria

The Prognostic Value of Serum Cytokines in Patients with Acute Ischemic Stroke

Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity

The effect of HIV infection and HAART on inflammatory biomarkers in a populationbased cohort of US women

Understanding cytokines part I: physiology and mechanism of action

Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects

The 'cytokine profile': a code for sepsis

C-reactive protein: a critical update

Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice

Towards salivary C-reactive protein as a viable biomarker of systemic inflammation

Increased proliferation of human synovial fibroblasts treated with recombinant interferon gamma

Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

Functions of IL-4 and control of its expression

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Measurement of cytokines in sweat patches and plasma in healthy women: validation in a controlled study

Critical appraisal of four IL-6 immunoassays

Elevated interleukin-6 and severe COVID-19: A meta-analysis

Acid aspirationinduced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms

IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors

12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

An inflammatory cytokine signature predicts COVID-19 severity and survival

IL-10: the master regulator of immunity to infection

Role of fibrin D-dimer testing in emergency medicine

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

Tumor necrosis factor signaling

Signal transduction by tumor necrosis factor and its relatives

Glutamate sensing in biofluids: Recent advances and research challenges of electrochemical sensors

Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

COVID-19 pandemic, coronaviruses, and diabetes mellitus

Innate immunity to virus infection

Principles of intracellular viral recognition

The COVID-19 Cytokine Storm; What We Know So Far

Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease

Into the eye of the cytokine storm. Microbiology and molecular biology reviews : MMBR

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies

Overview of the immune response

Lymphopenia in COVID-19: Therapeutic opportunities

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Interleukins 1 and 6 as main mediators of inflammation and cancer

Anti-inflammatory cytokines

The involvement and possible mechanism of pro-inflammatory tumor necrosis factor alpha (TNF-α) in thoracic ossification of the ligamentum flavum

Breath condensate pH in children with cystic fibrosis and asthma: a new noninvasive marker of airway inflammation?

Exhaled biomarkers

Relationships between adult asthma and oxidative stress markers and pH in exhaled breath condensate: a systematic review

COVID-19-Related Stroke

Inflammatory response induced by candidate biomaterials of an implantable microfabricated sensor

Unique Sensing Interface That Allows the Development of an Electrochemical Immunosensor for the Detection of Tumor Necrosis Factor α in Whole Blood

Saliva: an emerging biofluid for early detection of diseases

Immunological changes in response to exercise: influence of age, puberty, and gender. Medicine and science in sports and exercise

An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug and alcohol review

Preanalytical requirements of urinalysis

Finally, a simple solution to biofouling

Electrochemical Sensing of Cannabinoids in Biofluids: A Noninvasive Tool for Drug Detection

Anti-Biofouling Strategies for Long-Term Continuous Use of Implantable Biosensors

Preparation of novel electrochemical glucose biosensors for whole blood based on antibiofouling polyurethane-heparin nanoparticles

Design of a self-cleaning thermoresponsive nanocomposite hydrogel membrane for implantable biosensors

C-reactive Protein

A high sensitivity assay for the inflammatory marker C-Reactive protein employing acoustic biosensing

Label-free C-reactive protein electronic detection with an electrolyte-gated organic field-effect transistor-based immunosensor

Detection beyond Debye's length with an electrolytegated organic field-effect transistor

Electrochemical Detection of C-Reactive Protein in

An optimised electrochemical biosensor for the label-free detection of C-reactive protein in blood

Electrochemical detection of c-reactive protein based on anthraquinone-labeled antibody using a screen-printed graphene electrode

Single Frequency Impedance Analysis on Reduced Graphene Oxide Screen-Printed Electrode for Biomolecular Detection. Applied biochemistry and biotechnology

Occlusion phenomenon of redox probe by protein as a way of voltammetric detection of non-electroactive C-reactive protein

Immunosensor for electrodetection of the C-reactive protein in serum

Disposable immunosensors for C-reactive protein based on carbon nanotubes field effect transistors

Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Clinical features of patients infected with 2019 novel coronavirus in

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical and immunological features of severe and moderate coronavirus disease 2019

Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ciaa449

Sputum and salivary protein biomarkers and point-of-care biosensors for the management of COPD

The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis

Potential Role of Antiinterleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks

IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy

Salivary and serum interleukin-6 levels in proliferative verrucous leukoplakia

Using sweat to measure cytokines in older adults compared to younger adults: A pilot study

High levels of interleukin-6 in the exhaled breath condensate of patients with COPD

Interleukin-6 in COVID-19: a systematic review and meta-analysis

Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead

Interleukin-6 and prostate cancer progression

Interleukin-6 receptor pathways in abdominal aortic aneurysm

Cytokines in chronic obstructive pulmonary disease. The European respiratory journal. Supplement

Automated in Vivo Nanosensing of Breath-Borne Protein Biomarkers

Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer

A fully integrated electrochemical biosensor platform fabrication process for cytokines detection

interleukin-6 (IL-6) in real time

Graphene-based fully integrated portable nanosensing system for on-line detection of cytokine biomarkers in saliva

A Novel Label Free Electrochemical Magnetoimmunosensor for Human Interleukin-6

Label-free electrochemical aptasensor based on gold and polypyrrole nanoparticles for interleukin 6 detection

Ultrasensitive Label-Free Sensing of IL-6 Based on PASE Functionalized Carbon Nanotube Micro-Arrays with RNA-Aptamers as Molecular Recognition Elements

Tumor necrosis factor-α signaling in macrophages. Critical reviews in eukaryotic gene expression

Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases

Tumor necrosis factor (TNF) inhibitors

An aptasensor for electrochemical detection of tumor necrosis factor in human blood

Detecting multiple cellsecreted cytokines from the same aptamer-functionalized electrode

Voltammetric determination of tumor necrosis factor-α based on the use of an aptamer and magnetic nanoparticles loaded with gold nanoparticles

Label-free electrochemical immunosensor for detection of tumor necrosis factor α based on fullerenefunctionalized carbon nanotubes/ionic liquid

Label-free electrochemical immunosensor based on K3[Fe(CN)6] as signal for facile and sensitive determination of tumor necrosis factor-alpha

Development of a novel single sensor multiplexed marker assay

A Wearable and Deformable Graphene-Based Affinity Nanosensor for Monitoring of

Detection of tumor necrosis factor (TNF-α) in cell culture medium with label free electrochemical impedance spectroscopy

Viruses and interferons

Type 1 interferons as a potential treatment against COVID-19

Type I IFN immunoprofiling in COVID-19 patients

A sensitive electrochemical aptasensor for TNF-α based on bimetallic Ag@ Pt core-shell nanoparticle functionalized graphene nanostructures as labels for signal amplification

Electrochemical immunoplatform to improve the reliability of breast cancer diagnosis through the simultaneous determination of RANKL and TNF in serum

β-Lactamase label-based potentiometric biosensor for α-2 interferon detection

Evidence for glutamate as the olfactory receptor cell neurotransmitter

Functional Architecture of Olfactory Ionotropic Glutamate Receptors

Glutamate Excitotoxicity Is Involved in the Induction of Paralysis in Mice after Infection by a Human Coronavirus with a Single Point Mutation in Its Spike Protein

Nervous system involvement after infection with COVID-19 and other coronaviruses

Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Disposable sensor based on enzyme-free Ni nanowire array electrode to detect glutamate

Development of a novel micro biosensor for in vivo monitoring of glutamate release in the brain

Non-enzymatic simultaneous detection of l-glutamic acid and uric acid using mesoporous Co3O4 nanosheets

A non enzymatic glutamate sensor based on nickel oxide nanoparticle

L-Glutamate biosensor based on l-glutamate oxidase immobilized onto ZnO nanorods/polypyrrole modified pencil graphite electrode

An enzyme-based electrochemical biosensor probe with sensitivity to detect astrocytic versus glioma uptake of glutamate in real time in vitro

Exhaled breath condensate pH assays

Exhaled breath condensate acidification in acute lung injury

Multiplex analysis of cytokines in exhaled breath condensate

Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications

Detection of volatile organic compounds as biomarkers in breath analysis by different analytical techniques

Exhaled breath condensate collection in the mechanically ventilated patient

Standardization of exhaled breath condensate: effects of different de-aeration protocols on pH and H₂O₂ concentrations

Exhaled-breath condensate pH can be safely and continuously monitored in mechanically ventilated patients

Sampling and analyzing alveolar exhaled breath condensate in mechanically ventilated patients: a feasibility study

A fast, simple, and inexpensive method to collect exhaled breath condensate for pH determination

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19

Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis

Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases

White blood cell counting on smartphone paper electrochemical sensor

Hematologic parameters in patients with COVID-19 infection

Electrochemical magneto-actuated biosensor for CD4 count in AIDS diagnosis and monitoring

Electrochemical impedance biosensor with electrode pixels for precise counting of CD4 cells: A microchip for quantitative diagnosis of HIV infection status of AIDS patients

Single wall carbon nanotube electrode system capable of quantitative detection of CD4 + T cells

A micromachined high throughput Coulter counter for bioparticle detection and counting

D-Dimer and prothrombin fragment 1+ 2 in urine and plasma in patients with clinically suspected venous thromboembolism

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

Metabolic Syndrome and COVID-19 Mortality Among Adult Black Patients in New Orleans

Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after

SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management

Impedimetric immunosensor based on SWCNT-COOH modified gold microelectrodes for label-free detection of deep venous thrombosis biomarker

Low-Cost and Desktop-Fabricated Biosensor for Rapid and Sensitive Detection of Circulating D-Dimer Biomarker

A potentiometric immunosensor based on silver nanoparticles decorated ZnO nanotubes, for the selective detection of d-dimer

Electrochemical detection of D-dimer as deep vein thrombosis marker using single-chain D-dimer antibody immobilized on functionalized polypyrrole

Amperometric Magnetoimmunosensors for Direct Determination of D-Dimer in Human Serum

The SARS coronavirus nucleocapsid protein--forms and functions

Functionalized TiO2 Nanotube-Based Electrochemical Biosensor for Rapid Detection of SARS-CoV-2

SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor

SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

Label-Free Electrochemical Detection of DNA Hybridization: A Method for COVID-19 Diagnosis

Rapid, Ultrasensitive, and Quantitative Detection of SARS-CoV-2 Using Antisense Oligonucleotides Directed Electrochemical Biosensor Chip

A comprehensive definition for metabolic syndrome

The renin angiotensin system and the metabolic syndrome

Cardiovascular disease and COVID-19

Systemic Inflammation in Metabolic Syndrome: Increased Platelet and Leukocyte Activation, and Key Role of CX3CL1/CX3CR1 and CCL2/CCR2 Axes in Arterial Platelet-Proinflammatory Monocyte Adhesion

Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes

Role of Salivary Biomarkers in Detection of Cardiovascular Diseases (CVD)

The varying faces of IL-6: From cardiac protection to cardiac failure

Tumor necrosis factor in the heart

The role of TNF in cardiovascular disease

The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease

Advancing Point-of-Care (PoC) Testing Using Human Saliva as Liquid Biopsy

Global overview of drug demand and supply

Medicinal chemistry of cannabinoids

Pharmacokinetics and pharmacodynamics of cannabinoids

Neurological aspects of medical use of cannabidiol

Cannabidiolrecent advances

Cannabidiol claims and misconceptions

Cannabidiol, neuroprotection and neuropsychiatric disorders

In the eye of the COVID-19 cytokine storm

The trinity of COVID-19: immunity, inflammation and intervention

Cannabis roots: a traditional therapy with future potential for treating inflammation and pain. Cannabis and cannabinoid research

Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice

Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw

their chemistry and role against oxidative stress, inflammation, and cancer

Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?

Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?

Cannabis in cancer care

Integrating cannabis into clinical cancer care

The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS

Cannabis use in HIV for pain and other medical symptoms

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

Medical cannabis and mental health: a guided systematic review

Cannabinoidinduced apoptosis in immune cells as a pathway to immunosuppression

Cannabinoids and the Coronavirus

Impact of cannabis, cannabinoids, and endocannabinoids in the lungs

Olfactory and gustatory dysfunctions as a clinical presentation of mildto-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features

Guillain-Barré Syndrome Associated with SARS-CoV-2

Cannabis exposure is associated with a lower likelihood of neurocognitive impairment in people living with HIV

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors

Potential of cannabidiol for the treatment of viral hepatitis

Cannabis use improves retention and virological outcomes in patients treated for hepatitis C

Development of an ultra-sensitive electrochemical sensor for Δ9-tetrahydrocannabinol (THC) and its metabolites using carbon paper electrodes

Disposable screen printed sensor for the electrochemical detection of delta-9-tetrahydrocannabinol in undiluted saliva

Electrochemical study of delta-9-tetrahydrocannabinol by cyclic voltammetry using screen printed electrode, improvements in forensic analysis

A Novel Tetrahydrocannabinol Electrochemical Nano Immunosensor Based on Horseradish Peroxidase and Double-Layer Gold Nanoparticles

Molecularly imprinted carbon based electrodes for tetrahydrocannabinol sensing

Absorptive stripping voltammetry for cannabis detection

Hydroxypropyl-β-cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of Δ9-tetrahydrocannabinol

Use of screen-printed electrodes for quantification of cocaine and Δ 9-THC: adaptions to portable systems for forensic purposes

Voltammetric determination of Δ9-THC in glassy carbon electrode: An important contribution to forensic electroanalysis

A comparative study between two different conventional working electrodes for detection of Δ9-tetrahydrocannabinol using square-wave voltammetry: a new sensitive method for forensic analysis

Surface modification methods for electrochemical biosensors

Simultaneous detection of salivary Δ9-tetrahydrocannabinol and alcohol using a Wearable Electrochemical Ring Sensor

Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection

COVID-19 and risk of pulmonary fibrosis: The importance of planning ahead

J o u r n a l P r e -p r o o f • COVID19 infection can alter levels of biomarkers such as C-reactive protein, interleukins, glutamate, breath pH, TNF-α, interferons, hematological biomarkers, and D-dimer. Detecting these changes via electrochemical sensors can help assess the severity of a COVID-19 infection at the bedside.• Current electrochemical sensors can detect these biomarkers in biofluids within a certain range of detection, some of which correspond to the biomarker ranges that result from COVID-19 infection. These are presented in tabular form.• Metabolic syndrome is a comorbidity that can further aggravate a COVID-19 infection, inflammation, and long-term effects.• Cannabinoids have been previously used to treat inflammation. The use of cannabinoids is a potential frontier for treating COVID-19 patients, however; there is a lack of research.J o u r n a l P r e -p r o o f

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

The authors declare no credit author statement and no conflict of interest.